OncoCyte (NASDAQ:OCX) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a research report released on Friday. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reiterated a buy rating and set a $4.25 price objective on shares of OncoCyte in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, OncoCyte has a consensus rating of Hold and an average price target of $4.06.

OncoCyte Price Performance

OCX opened at $2.85 on Friday. The business’s 50-day moving average price is $3.10 and its two-hundred day moving average price is $2.93. OncoCyte has a 1 year low of $2.08 and a 1 year high of $4.34.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The firm had revenue of $0.10 million for the quarter.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.